Brief: Oxigene announces presentation of phase 2 data confirming that addition of Fosbretabulin to Bevacizumab significantly increases progression-free survival in recurrent Ovarian cancer
10/11/2014 08:00
Nov 10 (Reuters) - OXiGENE Inc OXGN.O : * Oxigene announces presentation of phase 2 data confirming that addition of fosbretabulin to bevacizumab significantly increases progression-free survival in recurrent ovarian cancer * Looks forward to discussing these findings with regulatory agencies to determine a potential path forward for fosbretabulin in ovarian cancer * Source text for Eikon ID:nGNXVCANFa ((Bangalore Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas